Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 (mut) measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, includi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Haematol
Main Authors: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2020
נושאים:
Haematological Malignancy ‐ Clinical
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://ncbi.nlm.nih.gov/pubmed/32458446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16722
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים